Outsourcing-Pharma RSS

Asuragen adds KRAS, BRAF testing for personalised med

nick.taylor@decisionnews.com — Thu, 02 Sep 2010 11:00:00 +0200

Asuragen is introducing KRAS and BRAF mutational testing services to support development of personalised colorectal cancer treatments.

Quintiles lands CF drug commercialisation contract

gareth.macdonald@decisionnews.com — Thu, 02 Sep 2010 11:00:00 +0200

Quintiles will help Australian drugmaker Pharmaxis launch its cystic fibrosis treatment Bronchitol in Europe under a contract announced yesterday.

BI opens ‘Centre of Competence’ opens as part of a €100m China plan

alexandria.pesic@decisionnews.com — Thu, 02 Sep 2010 11:00:00 +0200

Boehringer Ingelheim has opened its ‘Centre of Competence’ (CoC) in Shanghai to optimise API and chemical intermediates sourcing in China.

Accenture & ICRI partner for Indian clinical research training

nick.taylor@decisionnews.com — Thu, 02 Sep 2010 11:00:00 +0200

Accenture and ICRI have partnered to jointly develop a pharmacovigilance and clinical research programme for the Indian market.

Vetter moves US sales office to Illinois “hotspot”

gareth.macdonald@decisionnews.com — Thu, 02 Sep 2010 11:00:00 +0200

CMO Vetter Pharma has set up a US sales office in Skokie, Illinois to attract customers in growing Midwest drug industry hub.

BNC says nano approach can aid drug-target research

gareth.macdonald@decisionnews.com — Thu, 02 Sep 2010 11:00:00 +0200

Bio Nano Consulting (BNC) launches new fluorescent tag-free technique that it says can help evaluate protein stability and ligand binding in drug discovery.

Top strategies for recruiting and retaining trial participants

nick.taylor@decisionnews.com — Wed, 01 Sep 2010 11:00:00 +0200

Retention strategies, trial site evaluations and dedicated budgets should be used to recruit patients to, and keep them in, clinical trials, according to research.

ImmunoSolv & GBC merge; plan contract services growth

nick.taylor@decisionnews.com — Wed, 01 Sep 2010 11:00:00 +0200

ImmunoSolv is merging with Grampian BioConsultants (GBC) and plans to accelerate development of the contract research business.

TiGenix to spin-out drug discovery activities as Arcarios

alexandria.pesic@decisionnews.com — Wed, 01 Sep 2010 11:00:00 +0200

TiGenix to spin-out its discovery and development business as new small-molecule focused industry-academia consortium Arcarios.

ScinoPharm Taiwan to invest in U.S. Tanvex Biologics

alexandria.pesic@decisionnews.com — Wed, 01 Sep 2010 11:00:00 +0200

ScinoPharm, a Taiwan-based API maker invested Tanvex Biologics, expanding presence in US biosimilars contracting market.